James R. Sneed
Known title: CCO and VPCIK: 0001366900
James R. Sneed's purchase track record
James R. Sneed has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2025 | ALTO | $3K | +80.2% | +161.3% | +7.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALTO | ▼ Sell | Tax Withholding | 22,265 | $107K | 4/1/2026 | View on chart |
| ALTO | ▲ Buy | Grant | 30,794 | $0 | 3/17/2026 | View on chart |
| ALTO | ▲ Buy | Open Market | 3,176 | $3K | 8/13/2025 | View on chart |
| ALTO | ▲ Buy | Grant | 47,834 | $0 | 3/31/2025 | View on chart |
| ALTO | ▲ Buy | Grant | 71,660 | $0 | 3/20/2024 | View on chart |
| ALTO | ▲ Buy | Grant | 107,500 | $0 | 3/31/2023 | View on chart |
| ALTO | ▼ Sell | Tax Withholding | 15,763 | $109K | 4/1/2022 | View on chart |
| ALTO | ▲ Buy | Grant | 34,734 | $0 | 3/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
StoneX initiates coverage on Alto Ingredients with $7 target
StoneX has begun tracking Alto Ingredients, assigning a Buy rating and a price target of $7. This new analyst view places the stock within the current 52-week range of $0.99 to $6.11. The move adds to the existing analyst consensus, which currently averages a target of $9.00 based on two estimates.
StoneX initiates coverage on Alto Ingredients with $7 target. StoneX has begun tracking Alto Ingredients, assigning a Buy rating and a price target of $7. This new analyst view places the stock within the current 52-week range of $0.99 to $6.11. The move adds to the existing analyst consensus, which currently averages a target of $9.00 based on two estimates.